(:BIVV)
Business Focus: N/A
Mar 06, 2018 08:20 am ET
Consolidated Research: 2018 Summary Expectations for SandRidge Energy, BIOVERATIV INC, Ultra Clean, The Mosaic, Papa John's International, and Chegg — Fundamental Analysis, Key Performance Indications
NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SandRidge Energy, Inc. (NYSE:SD), BIOVERATIV INC...
Mar 06, 2018 07:30 am ET
Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease
Bioverativ
Inc. (NASDAQ: BIVV), a global biopharmaceutical company
dedicated to transforming the lives of people with rare blood disorders,
today announced that the first patient has been dosed in the Phase 3
clinical program of its investigational therapy BIVV009 for cold
agglutinin disease (CAgD). The Phase 3 program inclu
Mar 02, 2018 05:30 pm ET
IPG Photonics Set to Join S&P 500; ALLETE and LendingTree to Join S&P MidCap 400; New York Mortgage Trust, Global Net Lease and Finisar to Join S&P SmallCap 600
NEW YORK, March 2, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600:
Feb 14, 2018 07:00 am ET
Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A
Bioverativ
Inc. (NASDAQ: BIVV), a global biopharmaceutical company
dedicated to transforming the lives of people with rare blood disorders,
today announced the publication of a retrospective analysis
investigating the use of ELOCTATE® [Antihemophilic Factor (Recombinant),
Fc Fusion Protein] for immune tolerance induction
Feb 13, 2018 04:15 pm ET
Bioverativ Reports Fourth Quarter and Full Year 2017 Performance
Bioverativ
Inc. (NASDAQ: BIVV) today reported financial results for the fourth
quarter and full year of 2017.
Jan 24, 2018 02:32 pm ET
The Law Offices of Vincent Wong Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi
The Law Offices of Vincent Wong are investigating the Board of Directors
of Bioverativ Inc. (NASDAQGS: BIVV) for possible breaches of fiduciary
duty and other violations of state law in connection with the sale of
the Company to Sanofi. Under the terms of the deal, Bioverativ
shareholders will receive $105 for each Bioverativ share they own.
Jan 24, 2018 11:39 am ET
WeissLaw LLP Investigates Bioverativ Inc. Acquisition
NEW YORK, Jan. 24, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Bioverativ Inc. ("BIVV" or the "Company") (NASDAQ: BIVV) in connection with the proposed acquisition of the Company by French drugmaker Sanofi S.A. ("Sanofi"). Under the terms of the acquisition agreement, the Company's shareholders will receive $105.00 in cash for each BIVV share they own.
Jan 23, 2018 12:30 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Bioverativ Inc. Buyout
Rigrodsky & Long, P.A.:
Jan 23, 2018 09:00 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP:
Jan 22, 2018 02:57 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Bioverativ, Inc. - BIVV
NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors and Officers of Bioverativ, Inc. ("Bioverativ" or the "Company") (NasdaqGS: BIVV) for possible breaches of fiduciary duty.
Jan 22, 2018 11:45 am ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf
of Bioverativ Inc. (NASDAQ:BIVV) stockholders concerning the proposed
acquisition of the company by Sanofi (NYSE:SNY)
Jan 22, 2018 11:19 am ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Bioverativ Inc.
NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Bioverativ Inc. (NASDAQ: BIVV) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Sanofi SA. Stockholders will receive $105.00 for each share of Bioverativ Inc. that they hold. The transaction is valued at approximately $11.6 billion and is expected to close within the next three months.
Jan 22, 2018 10:44 am ET
BIOVERATIV INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
Rigrodsky & Long, P.A.:
Jan 22, 2018 10:21 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders – BIVV
The following statement is being issued by Levi & Korsinsky, LLP:
Jan 22, 2018 07:49 am ET
Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc.
SAN DIEGO, Jan. 22, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Bioverativ Inc., and Juno Therapeutics, Inc., as detailed below:
Jan 16, 2018 04:15 pm ET
Bioverativ to Report Fourth Quarter and Year-End 2017 Financial Results on February 13, 2018
Bioverativ
Inc. (NASDAQ: BIVV) today announced it will report fourth quarter
and year-end 2017 financial results on Tuesday, February 13, 2018, after
the market closes. The press release will be available in the “Investor
Relations” section of the company’s website at
Jan 02, 2018 04:15 pm ET
Bioverativ to Present at the 2018 J.P. Morgan Healthcare Conference
Bioverativ
Inc. (NASDAQ: BIVV) announced today that it will present at the 2018
J.P. Morgan Healthcare Conference. The event will be webcast live on
Monday, January 8, 2018 at 4:00 p.m. PST. To access the live webcast,
please visit Bioverativ’s Investors page at
Dec 22, 2017 04:05 pm ET
Bioverativ Announces 2018 Annual Meeting of Stockholders
Bioverativ
Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to
transforming the lives of people with rare blood disorders, announced
today that its 2018 Annual Meeting of Stockholders has been scheduled
for April 25, 2018.
Dec 11, 2017 02:47 pm ET
Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients
Bioverativ
Inc. (NASDAQ: BIVV), a global biopharmaceutical company
dedicated to transforming the lives of people with rare blood disorders,
today presented data demonstrating that BIVV009, its first-in-class
monoclonal antibody currently in Phase 3 clinical development for the
treatment of cold agglutinin disease (CAgD), wa
Dec 11, 2017 10:02 am ET
New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia B
Bioverativ
Inc. (NASDAQ:BIVV) and Swedish Orphan Biovitrum AB (publ)
(Sobi™) (STO:SOBI) today announced the results of a new, post-hoc
longitudinal analysis demonstrating that individualized dosing with
extended half-life therapy, ALPROLIX® [Coagulation Factor IX
(Recombinant), Fc Fusion Protein], every 14 or m
Dec 10, 2017 09:02 am ET
Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A
Bioverativ
Inc. (NASDAQ: BIVV) and Swedish Orphan Biovitrum AB (publ)
(Sobi™) (STO:SOBI) today announce the results of a new, post-hoc,
longitudinal analysis of the pivotal Phase 3 A-LONG study and ASPIRE
long-term extension study, showing that weekly prophylactic dosing with
its extended half-life therapy ELOCTATE®
Dec 09, 2017 09:02 am ET
ALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study
Bioverativ
Inc. (NASDAQ: BIVV), a global biopharmaceutical company
dedicated to transforming the lives of people with rare blood disorders,
today announced findings from a novel imaging study investigating
extravascular distribution of factor IX therapies, including its leading
extended half-life therapy, ALPROLIX®
Nov 27, 2017 07:30 am ET
U.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children with Hemophilia B
Bioverativ
Inc. (NASDAQ: BIVV), a global biopharmaceutical company
dedicated to transforming the lives of people with rare blood disorders,
today announced that the U.S. Food and Drug Administration (FDA) has
approved updated labeling for ALPROLIX® [Coagulation Factor IX
(Recombinant), Fc Fusion Protein], the leading exte
Nov 21, 2017 04:15 pm ET
Bioverativ to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Bioverativ
Inc. (NASDAQ: BIVV) announced today that it will present at the
Evercore ISI Biopharma Catalyst/Deep Dive Conference. The event will be
webcast live on Wednesday, November 29, 2017 at 10:15 a.m. EST. To
access the live webcast, please visit Bioverativ’s Investors page at
Nov 08, 2017 08:10 am ET
Detailed Research: Economic Perspectives on Wayfair, Allison Transmission, Paychex, Bioverativ, Diamond Offshore, and Stryker – What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Wayfair Inc. (NYSE:W), Allison Transmission Holdings,...
Nov 01, 2017 04:00 pm ET
Bioverativ to Present at the Credit Suisse 2017 Healthcare Conference
Bioverativ
Inc. (NASDAQ: BIVV) announced today that it will present at the
Credit Suisse 2017 Healthcare Conference. The event will be webcast live
on Tuesday, November 7, 2017 at 5:55 p.m. EST / 3:55 p.m. MST. To access
the live webcast, please visit Bioverativ’s Investors page at
Nov 01, 2017 09:40 am ET
Bioverativ to Present New Data on Rare Blood Disorder Programs at ASH 2017 Annual Meeting
Bioverativ
Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to
transforming the lives of people with rare blood disorders, today
announced that it will present data showcasing its work to advance
therapies for people affected by hemophilia, cold agglutinin disease
(CAgD), sickle cell disease and beta-thalassemia
Oct 31, 2017 08:00 am ET
Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment with ELOCTATE®
Bioverativ
Inc. (NASDAQ: BIVV) and Swedish
Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announc
Oct 26, 2017 04:15 pm ET
Bioverativ Reports Third Quarter 2017 Performance
Bioverativ
Inc. (NASDAQ: BIVV) today reported financial results for the third
quarter of 2017.
Oct 02, 2017 08:30 am ET
Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia
RICHMOND, Calif. and WALTHAM, Mass., Oct. 2, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, and Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for hemophilia and other rare blood disorders, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. Sangamo and Bi
Jan 24, 2017 06:10 pm ET
LogMeIn and Bioverativ Set to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK, Jan. 24, 2017 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.